Francisco Revert-Ros

Dr. Francisco Revert-Ros

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Angel RayaAngel Raya
Angel Raya
FRFrancisco Revert-Ros
Francisco Revert-Ros
PMPilar Martinez
Pilar Martinez
SNSamuel Navarro
Samuel Navarro
EREsther Roselló
Esther Roselló
JSJuan Saus
Juan Saus
The non-collagenous C-terminal domain of the α3 chain of collagen IV is the autoantigen in Goodpasture disease, an autoimmune disorder described only in humans. Specific N-terminal phosphorylation is a biological feature unique to the human domain when compared with other homologous domains lacking immunopathogenic potential. We have recently cloned from a HeLa-derived cDNA library a novel serine/threonine kinase (Goodpasture antigen-binding protein (GPBP)) that phosphorylates the N-terminal region of the human domain (Raya, A. Revert, F, Navarro, S. and Saus J. (1999) J. Biol. Chem. 274, 12642–12649). We show here that the pre-mRNA of GPBP is alternatively spliced in human tissues and that the most common transcript found encodes GPBPΔ26, a molecular isoform devoid of a 26-residue serine-rich motif. Recombinantly expressed GPBPΔ26 exhibits lower activity than GPBP, due at least in part to a reduced ability of GPBPΔ26 to interact and to form very active high molecular weight aggregates. In human tissues, GPBP shows a more limited expression than GPBPΔ26 but displays a remarkable preference for the small vessels and for histological structures targeted by natural autoimmune responses including alveolar and glomerular basement membranes, the two main targets in Goodpasture disease. GPBP expression is, in turn, up-regulated in the striated muscle of a Goodpasture patient and in other autoimmune conditions including cutaneous lupus erythematosus, pemphigoid, and lichen planus.

19 January 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
FRFernando Revert
Fernando Revert
FRFrancisco Revert-Ros
Francisco Revert-Ros
RBRaül Blasco
Raül Blasco
AAAida Artigot
Aida Artigot
ELErnesto López-Pascual
Ernesto López-Pascual
JSJuan Saus
Juan Saus
Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden

1 November 2007 in The American Journal of Pathology
Verified
Journal Article
Closed access
FRFernando Revert
Fernando Revert
RMRamón Merino
Ramón Merino
CMCarlos Monteagudo
Carlos Monteagudo
JMJesús Macias
Jesús Macias
APAmando Peydró
Amando Peydró
JSJuan Saus
Juan Saus

1 October 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FRFernando Revert
Fernando Revert
IVIgnacio Ventura
Ignacio Ventura
PMPilar Martinez
Pilar Martinez
FGFroilán Granero-Moltó
Froilán Granero-Moltó
FRFrancisco Revert-Ros
Francisco Revert-Ros
JSJuan Saus
Juan Saus
Goodpasture-antigen binding protein (GPBP) is a nonconventional Ser/Thr kinase for basement membrane type IV collagen. Various studies have questioned these findings and proposed that GPBP serves as transporter of ceramide between the endoplasmic reticulum and the Golgi apparatus. Here we show that cells expressed at least two GPBP isoforms resulting from canonical (77-kDa) and noncanonical (91-kDa) mRNA translation initiation. The 77-kDa polypeptide interacted with type IV collagen and localized as a soluble form in the extracellular compartment. The 91-kDa polypeptide and its derived 120-kDa polypeptide associated with cellular membranes and regulated the extracellular levels of the 77-kDa polypeptide. A short motif containing two phenylalanines in an acidic tract and the 26-residue Ser-rich region were required for efficient 77-kDa polypeptide secretion. Removal of the 26-residue Ser-rich region by alternative exon splicing rendered the protein cytosolic and sensitive to the reduction of sphingomyelin cellular levels. These and previous data implicate GPBPs in a multicompartmental program for protein secretion (i.e. type IV collagen) that includes: 1) phosphorylation and regulation of protein molecular/supramolecular organization and 2) interorganelle ceramide trafficking and regulation of protein cargo transport to the plasma membrane.

27 September 2005 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
FGFroilán Granero-Moltó
Froilán Granero-Moltó
FRFernando Revert
Fernando Revert
FRFrancisco Revert-Ros
Francisco Revert-Ros
SLSergio Lainez
Sergio Lainez
PMPilar Martinez
Pilar Martinez
JSJuan Saus
Juan Saus

Verified
Journal Article
Open access
PDF file
FRFrancisco Revert-Ros
Francisco Revert-Ros
IVIgnacio Ventura
Ignacio Ventura
JRJesús Ángel Prieto Ruiz
Jesús Ángel Prieto Ruiz
JHJosé M. Hernández-Andreu
José M. Hernández-Andreu
Fernando RevertFernando Revert
Fernando Revert
Collagen, a versatile family of proteins with 28 members and 44 genes, is pivotal in maintaining tissue integrity and function. It plays a crucial role in physiological processes like wound healing, hemostasis, and pathological conditions such as fibrosis and cancer. Collagen is a target in these processes. Direct methods for collagen modulation include enzymatic breakdown and molecular binding approaches. For instance, Clostridium histolyticum collagenase is effective in treating localized fibrosis. Polypeptides like collagen-binding domains offer promising avenues for tumor-specific immunotherapy and drug delivery. Indirect targeting of collagen involves regulating cellular processes essential for its synthesis and maturation, such as translation regulation and microRNA activity. Enzymes involved in collagen modification, such as prolyl-hydroxylases or lysyl-oxidases, are also indirect therapeutic targets. From another perspective, collagen is also a natural source of drugs. Enzymatic degradation of collagen generates bioactive fragments known as matrikines and matricryptins, which exhibit diverse pharmacological activities. Overall, collagen-derived peptides present significant therapeutic potential beyond tissue repair, offering various strategies for treating fibrosis, cancer, and genetic disorders. Continued research into specific collagen targeting and the application of collagen and its derivatives may lead to the development of novel treatments for a range of pathological conditions.